Long-term use of ranibizumab for the treatment of age-related macular degeneration: a review of the clinical and cost-effectiveness and guidelines
CADTH
Record ID 32014000779
English
Authors' recommendations:
Treatment of AMD with ranibizumab and bevacizumab appeared to have similar effects on visual acuity. Monthly dosing with ranibizumab resulted in a greater gain in visual acuity than as needed dosing. In long-term follow-up, ranibizumab was well-tolerated for 4 or more years and remained more effective than no treatment. Incremental cost-effectiveness ratios (ICERs) were reported in two cost studies. Treatment with monthly ranibizumab was dominated by monthly bevacizumab. The results varied depending on the dosing regimen and length of treatment with the drugs. However, bevacizumab does not have a Health Canada indication for the treatment of AMD.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/pdf/htis/apr-2014/RC0533%20Lucentis%20for%20AMD%20final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Bevacizumab
- Wet Macular Degeneration
- Antibodies, Monoclonal, Humanized
- Angiogenesis Inhibitors
- Intravitreal Injections
- Ranibizumab
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
<p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.